Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

18. April 2023 09:00 ET | Quelle: Elevar Therapeutics

Elevar Therapeutics Presents AACR 2023 Poster Demonstrating Rivoceranib as Most Selective VEGFR-2 Inhibitor When Compared to Other TKIs With Known Activity Against VEGFR-2

ORLANDO, Fla., April 18, 2023 (GLOBE NEWSWIRE) -- Elevar Therapeutics, Inc., a fully integrated biopharmaceutical company dedicated to elevating treatment experiences and outcomes for patients who...
11. November 2021 11:15 ET | Quelle: Research Nester

Receptor Tyrosine Kinase Treatment Market Driven by High Implementation of Targeted Therapy to Treat Cancer on Molecular Level; Global Market to Generate Over USD 102 Billion Revenue by 2030, Witnessing a CAGR of 7% over 2022-2030

New York, Nov. 11, 2021 (GLOBE NEWSWIRE) -- According to W.H.O. (World Health Organisation), cancer is the second leading cause of death in the world and accounted for nearly 10 million deaths in...
09. Februar 2018 09:45 ET | Quelle: Lixte Biotechnology Holdings, Inc.

LB-100 and LB-102, Lixte Biotechnology’s Protein Phosphatase 2A Inhibitors, Sensitize BCR-ABL Leukemia Stem Cells to Targeted Therapy with Tyrosine Kinase Inhibitors

EAST SETAUKET, NY, Feb. 09, 2018 (GLOBE NEWSWIRE) -- Lixte Biotechnology Holdings, Inc. (OTCQB: LIXT) noted that investigators at the Terry Fox Laboratory, British Columbia Cancer Agency, Vancouver,...